You have accessJournal of UrologySexual Function/Dysfunction: Surgical Therapy III1 Apr 2017PD25-07 DURASPHERE AS NEW AGENT FOR THE TREATMENT OF HYPERMOBILE GLANS Jared J. Wallen, SK Madiraju, KG Tayon, MS Gross, RE Carrion, and PE Perito Jared J. WallenJared J. Wallen More articles by this author , SK MadirajuSK Madiraju More articles by this author , KG TayonKG Tayon More articles by this author , MS GrossMS Gross More articles by this author , RE CarrionRE Carrion More articles by this author , and PE PeritoPE Perito More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1202AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Despite proper sizing and placement of a penile implant, a subset of patients present postoperatively with glanular hypermobility. This is characterized by sensation of a soft glans penis, pain during intercourse associated with cylinder tip pressure, or the appearance of droopy glans with maximal inflation. Previous studies have discussed the use of PDE5 inhibitors and/or intraurethral alprostadil to treat the hypermobile glans. In this study we present our results of subcoronal Coloplast (Minneapolis, MN) Durasphere® injections as a surgical treatment for the hypermobile glans. METHODS Durasphere is a safe, sterile bulking agent composed of carbon-coated zirconium beads suspended in a water based beta-glucan gel. It has long been used as a bulking agent in the treatment of urinary incontinence caused by intrinsic sphincter deficiency (ISD). This is a retrospective review of 16 patients who underwent glanular bulking with Durasphere by a single surgeon from 2014-16. Patient data were compiled after extensive review of operative reports, inpatient notes, consult notes, and follow-up visits. RESULTS Sixteen patients underwent a total of 61 subcoronal Durasphere injections (mean 3.6, range 2-8). Fifteen of these patients have been seen in follow-up on average 50.5 weeks since their injections. 86.6% reported satisfaction with their treatment regimen quoting reduced or absent pain during intercourse and subjectively improved stability of their glans penis as reasons for satisfaction. 3 adverse events have been noted but all have healed with conservative management and no patients have lost their implant. CONCLUSIONS Durasphere has a safe and effective history in ISD treatment and our initial data suggests that similarly successful results are obtainable for glanular hypermobility treatment in experienced hands. We believe subcoronal Durasphere injections should be a viable option in the armamentarium of treatments for true glanular hypermobility due to high patient satisfaction, ease of intervention, and low adverse events. Proper diagnosis requires expert evaluation to ensure that the penile implant is appropriately sized and positioned in order to rule out floppy glans syndrome and SST deformity. As opposed to true glanular hypermobility, these conditions are caused by an undersized implant and require surgical revision. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e504 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Jared J. Wallen More articles by this author SK Madiraju More articles by this author KG Tayon More articles by this author MS Gross More articles by this author RE Carrion More articles by this author PE Perito More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...